Median DpR was also better in the chemotherapy plus anti EGFR mAb versus the chemotherapy plus bevacizumab irrespective of tumor locations (FIRE-3 42.0% vs 30.8% for left-sided; 25.8% vs 17.7% for right-sided; PEAK 70% vs 48% for left-sided, 50% vs 45% for right-sided). This evidence concerns the gene EGFR and neoplasm.